Csp Nasp Question Bank Plus Csp Handbook Questions

RB is a 20 year old female recently approved for CF treatment with Trikafta® (elexacaftor/tezacaftor/ivacaftor). She is homozygous for the F508 del mutation in the CFTR gene and meets criteria for treatment with this medication. Her current medications include inhaled albuterol, normal saline, tobramycin, Advair® and Pulmozyme®. She is also taking buspirone, cetirizine, vitamin D3, insulin (regular and long acting), montelukast, omeprazole, and Creon®. What is an important counseling point to cover with RB? Trikafta® should be taken with a high fat containing meal and she should avoid food or drink containing grapefruit. Trikafta® is taken once a day with a high fat containing meal. Patient can discontinue inhaled medications once she starts Trikafta® None of the above Trikafta® should be taken with a high fat containing meal and she should avoid food or drink containing grapefruit. AJ is a 32 year old female who presents to clinic 5 years post transplant. She and her husband are considering starting a family and would like to know if it is safe for her to become pregnant. Her post transplant immunosuppression regimen consists of tacrolimus 2mg BID, mycophenolate mofetil 1000mg BID, and prednisone 5mg daily. Assuming she has no other comorbidities, what recommendations would you make concerning her medication therapy if she is wanting to conceive? Patients cannot get pregnant post transplant Discontinue tacrolimus and start cyclosporine modified Discontinue mycophenolate mofetil and start Azathioprine No changes to medication therapy Discontinue mycophenolate mofetil and start Azathioprine M